Scans reveal lithium distribution in bipolar disorder
· Medical Xpressedited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
A revolutionary scanning technique has revealed that lithium MRI is a powerful tool for studying how the drug interacts with the brain and could offer more personalized treatment for bipolar disorder.
This paves the way for the medical community to better understand lithium's effectiveness and agree on the best prescribing advice.
The scans were used for the first time to investigate lithium dosing schedules in bipolar disorder in an innovative study conducted by researchers at Newcastle University, UK, and Technische Universität Dresden, Germany. It is published in The Lancet Psychiatry and reveals:
- For once- and twice-daily dosing, blood and brain lithium levels did not differ at the standard 12-hours-post-dose monitoring time point
- Brain lithium closely matched blood lithium levels across the day and was more stable with twice-daily dosing
- Brain lithium levels were higher in white matter than gray matter
Lithium is an effective long-term treatment for bipolar disorder, but prescribing practice varies, and it is common for it to be given either once or twice daily. While both practices are equally effective, there may be differences in side effects because once-daily use results in higher nighttime peaks but lower daytime levels in the blood.
It has been argued that these peaks and troughs are smoothed out when lithium is absorbed by the brain, but this study shows that brain and blood levels are closely matched across the day.
For medical teams, the finding of comparable brain levels at the standard 12-hour postdose measurement is reassuring and will inform future guidance on monitoring requirements.
The differences seen in brain lithium patterns between the two regimens may increase choice, allowing prescribers and patients to consider the option that best fits an individual's needs and preferences, such as convenience, treatment adherence, individual side effects and natural daily body rhythms (circadian processes).
A tool for tailored treatment
Dr. David Cousins, director of the Newcastle Magnetic Resonance Center, clinical senior lecturer at Newcastle University and honorary consultant psychiatrist at CNTW NHS Foundation Trust, said, "Lithium is the most effective long-term treatment for bipolar disorder, preventing episodes of illness and reducing the risk of suicide. Not everyone responds to lithium, but for those who do, it is important to individualize treatment to get the best out of this medication.
"This study shows that lithium MRI is a powerful tool for studying how the drug interacts with the brain and could support more personalized treatment in future.
"This may be the oldest drug available for bipolar disorder, but our findings, which provide a better understanding of how it works in practice, mean it should remain at the forefront of developments."
The study employed 7Li MRI, a multinuclear imaging technique developed at Newcastle University and established in centers across Europe in conjunction with CEA Neurospin Paris as part of the Horizon 2020 R-LiNK initiative.
Conducted in Dresden, 41 white European patients who were stable (euthymic) on lithium treatment (20 once daily, 21 twice daily) underwent three consecutive 7Li MRI scans and matched serum sampling over a 10-hour period. This is the largest 7Li MRI study to date and the first to perform repeated measures in bipolar disorder.
Professor Peter Thelwall, professor of magnetic resonance physics and director of the Center for In Vivo Imaging at Newcastle University, said, "This new imaging technique allows us to directly visualize a drug in the brain and address important clinical questions. Our research program is also driving advances in the capability of this technique to maximize the scope of its application for patient benefit."
The findings, from a collaboration between expert centers, represent a key output from a network of centers recently equipped with 7Li MRI.
Publication details
Philipp Ritter et al, Brain lithium temporospatial kinetics in bipolar disorder: a repeated-measures 7Li MRI study of dosing regimens in Germany, The Lancet Psychiatry (2026). DOI: 10.1016/s2215-0366(26)00153-7
Journal information: The Lancet Psychiatry
Key medical concepts
Clinical categories
PsychiatryDiagnostic radiology Provided by Newcastle University Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Scans reveal lithium distribution in bipolar disorder (2026, June 29) retrieved 30 June 2026 from https://medicalxpress.com/news/2026-06-scans-reveal-lithium-bipolar-disorder.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.